Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. (Q35796527)
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. |
scientific article |
Statements
1 reference
Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. (English)
1 reference
C C Bjorklund
1 reference
L Lu
1 reference
J Kang
1 reference
P R Hagner
1 reference
C G Havens
1 reference
M Amatangelo
1 reference
M Wang
1 reference
Y Ren
1 reference
S Couto
1 reference
M Breider
1 reference
Y Ning
1 reference
A K Gandhi
1 reference
T O Daniel
1 reference
R Chopra
1 reference
A Klippel
1 reference
A G Thakurta
1 reference
2 October 2015
1 reference
1 reference
5
1 reference
e354
1 reference
Identifiers
1 reference
1 reference
1 reference